TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in validated preclinical models TRV045 did not show a statistically significant effect in preliminary preclinical model of epileptogenesis, but results provide direction for additional NIH-initiated studies in epilepsy preventi ...

公司概况 - 公司是一家专注于开发和商业化针对中枢神经系统疾病患者的新药物的生物制药公司[12] - 公司自2007年开始运营以来，一直致力于商业化和研发，包括非临床研究和临床试验，但从未盈利[12] 财务状况 - 截至2024年3月31日，公司累计亏损达到5.957亿美元，2024年第一季度净亏损为7678万美元[12] - 公司的现金及现金等价物余额不足以支持未来一年的运营，存在实质性疑虑公司能否作为持续经营实体[12] - 公司计划通过股权或债务融资，或战略交易筹集额外资金，以缓解持续经营风险[12] 财务报表 - 公司的功能货币是美元，财务报表符合美国通用会计准则[13] - 2024年3月31日的财务报表已经进行了必要的调整，以公平呈现公司的资产负债表、损益表和现金流量表[13] - 公司在财务报表中使用了重要的估计，包括股权激励费用、股权奖励的公允价值、研发成本的会计处理等[17] 销售与收入 - 产品销售收入在满足客户义务后的时间点上确认，主要通过批发商销售[19] - 公司在交易价格中包括了可变考虑因素，如分销商回扣、及时付款折扣、分销服务费和产品退货[21] - 公司对分销商回扣进行估计，并在销售时减少收入[22] 股权和债务 - 公司贷款余额为31,317美元，利率为7.00%，到期日为2022年3月[35] - 公司在2023年12月通过出售预融资认股权证和行使认股权证获得了总计3.5百万美元[40] - 公司在2024年3月31日有384,717股股票期权可行使，行权价格为35.61美元[41] 经营活动 - 公司在2024年第一季度实现了20000美元的产品收入，较去年同期的6000美元增长了14000美元[76] - 公司在2024年第一季度的净亏损为7678万美元，较去年同期的7819万美元减少了141万美元[76] - 公司每个季度都会审查批发商手中的OLINVYK库存量，以评估预期产品退货的可能性[78] 现金流 - 2024年第一季度经营活动净现金流为负9,420万美元，较去年同期减少了1,454万美元[90] - 2024年第一季度融资活动净现金流为负3万美元[91] - 截至2024年3月31日，公司累计赤字为5.957亿美元，运营资金为1,880万美元，现金及现金等价物为2,360万美元[87]

Exhibit 99.1 Trevena Reports First Quarter 2024 Results and Provides Business Update For the first quarter of 2024, the Company reported a net loss attributable to common stockholders of $7.7 million, or $0.36 per share, compared to $7.8 million, or $0.81 per share in the first quarter of 2023. Cash and cash equivalents were $23.6 million as of March 31, 2024. On May 13, 2024, the Company received a decision letter from the Nasdaq Hearings Panel granting the Company an extension until August 28, 2024, subje ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1469215 (State or Other Juri ...

Exhibit 99.1 Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 1, 2024 (GLOBE NEWSWIRE) –Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for ...

Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Barry Shin - Senior Vice President, Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Senior Vice President, Chief Medical Officer Daniel Clauw - Key Opinion Leader and Paid Scientific Consultant Conference Call Participants Jason Butler - JMP Securities Douglas Tsao - H.C. Wainwright Operator Greetings and welcome to Trevena, Inc. Third Quarter 2023 Ea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdictio ...

Trevena, Inc. (NASDAQ:TRVN) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Operator Hello and welcome to Trevena, Inc. First Quarter 2023 Earnings Call. All participants will be in listen only mode. [Operator Instruc ...

Existing S1PR-targeted drugs, however, are ill-suited for CNS indications due to known: Lymphopenia Pulmonary AEs Cardiac AEs Ophthalmologic AEs 1) Sim-Selley et al., Journal of Pharmacology & Experimental Therapeutics, 2018. 2) Sim-Selley et al, Journal of Neurochemistry, 2008. 3) Gol et al., European Journal of Pharmaceutical Sciences, 2017. 4) Leo et al, CNS & Neurological Disorders - Drug Targets, 2017. 5) Choi, et al. PNAS 2011. 25 TRV045: Novel MOA, Selective S1PR % non-responseto pain stimulus Revers ...